Working Toward A Cure: Janssen’s Multiple Myeloma Strategy
T-cell Engagers, CAR-T Therapy Build On Darzalex Success
Executive Summary
Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.
You may also be interested in...
J&J’s Growth Plan Calls For Mega-Blockbusters And A Leading Oncology Franchise
Johnson & Johnson laid out long-term revenue growth guidance and plans for its Innovative Medicines pipeline during an R&D day.
J&J Continues Signaling Aggressive M&A Approach To Drive Growth
Johnson & Johnson reported disappointing Q1 sales for its COVID-19 vaccine but called the Carvykti launch solid and discussed plans for further diversification of its multiple myeloma portfolio.
Janssen And Sanofi Keep Mum On EU Fast-Track Request Outcomes
Teclistamab and nirsevimab may or not be fast-tracked when their sponsors – Janssen-Cilag and Sanofi, respectively – file for pan-EU approval. In the meantime, a total of seven filings are currently benefiting from the accelerated assessment mechanism at the European Medicines Agency.